Key result
Intracoronary alteplase fails to reduce microvascular obstruction during primary PCI vs. placebo.
Why the study?
Microvascular obstruction commonly affects STEMI patients and is associated with adverse outcomes, but whether early low-dose intracoronary alteplase after reperfusion reduces it was unknown.
Does adjunctive low-dose intracoronary alteplase infused early after coronary reperfusion and before stent implantation during primary PCI reduce microvascular obstruction in patients presenting within 6 hours of acute STEMI?
RCT (n=440)
Double-blind
1:1:1 randomized permuted blocks of length 6, stratified by location of STEMI (anterior vs nonanterior) and study site
Yes
Does adjunctive low-dose intracoronary alteplase infused early after coronary reperfusion and before stent implantation during primary PCI reduce microvascular obstruction in patients presenting within 6 hours of acute STEMI?
Adjunctive low-dose intracoronary alteplase administered during primary PCI for acute STEMI does not reduce microvascular obstruction and is not supported for clinical use.
Answers are grounded in this paper and cite their sources.
Low-dose intracoronary alteplase during primary PCI should not be used; confirms lack of microvascular obstruction benefit in STEMI.
Importance: Microvascular obstruction commonly affects patients with acute ST-segment elevation myocardial infarction (STEMI) and is associated with adverse outcomes. Objective: To determine whether a therapeutic strategy involving low-dose intracoronary fibrinolytic therapy with alteplase infused early after coronary reperfusion will reduce microvascular obstruction. Design, Setting, and Participants: Between March 17, 2016, and December 21, 2017, 440 patients presenting at 11 hospitals in the United Kingdom within 6 hours of STEMI due to a proximal-mid-vessel occlusion of a major coronary artery were randomized in a 1:1:1 dose-ranging trial design. Patient follow-up to 3 months was completed on April 12, 2018. Interventions: Participants were randomly assigned to treatment with placebo (n = 151), alteplase 10 mg (n = 144), or alteplase 20 mg (n = 145) by manual infusion over 5 to 10 minutes. The intervention was scheduled to occur early during the primary PCI procedure, after reperfusion of the infarct-related coronary artery and before stent implant. Main Outcomes and Measures: The primary outcome was the amount of microvascular obstruction (% left ventricular mass) demonstrated by contrast-enhanced cardiac magnetic resonance imaging (MRI) conducted from days 2 through 7 after enrollment. The primary comparison was the alteplase 20-mg group vs the placebo group; if not significant, the alteplase 10-mg group vs the placebo group was considered a secondary analysis. Results: Recruitment stopped on December 21, 2017, because conditional power for the primary outcome based on a prespecified analysis of the first 267 randomized participants was less than 30% in both treatment groups (futility criterion). Among the 440 patients randomized (mean age, 60.5 years; 15% women), the primary end point was achieved in 396 patients (90%), 17 (3.9%) withdrew, and all others were followed up to 3 months. In the primary analysis, the mean microvascular obstruction did not differ between the 20-mg alteplase and placebo groups (3.5% vs 2.3%; estimated difference, 1.16%; 95% CI, -0.08% to 2.41%; P = .32) nor in the analysis of 10-mg alteplase vs placebo groups (2.6% vs 2.3%; estimated difference, 0.29%; 95% CI, -0.76% to 1.35%; P = .74). Major adverse cardiac events (cardiac death, nonfatal MI, unplanned hospitalization for heart failure) occurred in 15 patients (10.1%) in the placebo group, 18 (12.9%) in the 10-mg alteplase group, and 12 (8.2%) in the 20-mg alteplase group. Conclusions and Relevance: Among patients with acute STEMI presenting within 6 hours of symptoms, adjunctive low-dose intracoronary alteplase given during the primary percutaneous intervention did not reduce microvascular obstruction. The study findings do not support this treatment. Trial Registration: ClinicalTrials.gov Identifier: NCT02257294.
No takes yet. Share an insight, caveat, or question.
McCartney et al. (2019) conducted an RCT in Acute ST-segment elevation myocardial infarction (STEMI) (n=440). Intracoronary alteplase vs. Placebo was evaluated on Amount of microvascular obstruction (% of left ventricular mass) demonstrated by late gadolinium-enhanced cardiac MRI from days 2 through 7 after enrollment (MD 1.16%, 95% CI -0.08% to 2.41%, p=0.32). Adjunctive low-dose intracoronary alteplase during primary PCI did not reduce microvascular obstruction compared to placebo.
Synapse has enriched 10 related papers. Consider them for comparative context: